Gustavo Forteza, MD
General Practice · Hialeah Gardens, FLNPI 1770569196
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $818 and has fallen 97.5% since, to $21 in 2025. Among general practice clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$396
- Sunovion Pharmaceuticals Inc.$293
- AbbVie$274
- Novartis$129
- Pfizer$127
- Novo Nordisk$119
- plus $687 from 12 others
What the payments were for
- Food & beverage$2,025100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $396 |
| Sunovion Pharmaceuticals Inc. | 16 | $293 |
| AbbVie(2 entities) | 18 | $274 |
| Novartis | 6 | $129 |
| Pfizer | 5 | $127 |
| Novo Nordisk | 6 | $119 |
| Boehringer Ingelheim | 5 | $118 |
| Johnson & Johnson | 6 | $115 |
| Astellas Pharma US Inc | 4 | $86 |
| Bayer | 3 | $64 |
| Smith+Nephew | 2 | $62 |
| Amarin Pharma, Inc. | 3 | $60 |
| Exact Sciences | 2 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| GSK | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Merck | 1 | $20 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$2,025 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 122 | $81,273 |
| EliquisApixaban | 109 | $71,071 |
| OzempicSemaglutide | 32 | $39,646 |
| RestasisCyclosporine | 56 | $37,188 |
| XareltoRivaroxaban | 55 | $35,743 |
| EntrestoSacubitril/Valsartan | 36 | $33,058 |
| MounjaroTirzepatide | 25 | $26,864 |
| JanuviaSitagliptin Phosphate | 36 | $21,935 |
| LinzessLinaclotide | 33 | $19,869 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 27 | $14,978 |
| JardianceEmpagliflozin | 19 | $14,280 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,779 |
| VascepaIcosapent Ethyl | 27 | $13,097 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $12,068 |
| SynjardyEmpagliflozin/Metformin Hcl | 15 | $10,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $396 | $85,088140 claims |
| PfizerEliquis | $127 | $71,071109 claims |
| AbbVieRestasis, Linzess, Lumigan | $274 | $63,470115 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $118 | $39,98161 claims |
| Novo NordiskOzempic | $119 | $39,64632 claims |
| Johnson & JohnsonXarelto | $115 | $35,74355 claims |
| MerckJanuvia, Janumet | $20 | $34,00352 claims |
| NovartisEntresto | $129 | $33,05836 claims |
| Lilly USA, LLCMounjaro | $15 | $26,86425 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $35 | $22,14741 claims |
| Smith+NephewSantyl | $62 | $5,70017 claims |
| Astellas Pharma US IncMyrbetriq | $86 | $5,28013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.
Other general practice in Hialeah Gardens
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
- Rickie FergusonPembroke Pines$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.